Cambridge Investment Research Advisors Inc. bought a new position in Amedisys Inc (NASDAQ:AMED) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,735 shares of the health services provider’s stock, valued at approximately $674,000.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Federated Investors Inc. PA raised its position in shares of Amedisys by 2.3% in the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after acquiring an additional 44 shares during the period. State of Alaska Department of Revenue raised its holdings in Amedisys by 2.3% during the 1st quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock worth $157,000 after buying an additional 70 shares during the period. State Board of Administration of Florida Retirement System raised its holdings in Amedisys by 0.5% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 19,658 shares of the health services provider’s stock worth $1,235,000 after buying an additional 93 shares during the period. Suntrust Banks Inc. raised its holdings in Amedisys by 2.0% during the 1st quarter. Suntrust Banks Inc. now owns 5,465 shares of the health services provider’s stock worth $279,000 after buying an additional 107 shares during the period. Finally, Municipal Employees Retirement System of Michigan grew its stake in shares of Amedisys by 1.8% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 6,370 shares of the health services provider’s stock worth $325,000 after acquiring an additional 110 shares in the last quarter. 96.80% of the stock is currently owned by institutional investors.
Amedisys Inc (NASDAQ AMED) opened at 52.03 on Friday. The firm’s 50-day moving average price is $50.02 and its 200 day moving average price is $54.86. The firm has a market cap of $1.76 billion, a P/E ratio of 44.47 and a beta of 0.84. Amedisys Inc has a 52 week low of $34.58 and a 52 week high of $65.91.
Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.12. The business had revenue of $378.80 million for the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.42 EPS. Equities analysts forecast that Amedisys Inc will post $2.21 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was published by BBNS and is owned by of BBNS. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/10735-shares-in-amedisys-inc-amed-acquired-by-cambridge-investment-research-advisors-inc/1610471.html.
Several research firms recently weighed in on AMED. Royal Bank Of Canada reissued a “hold” rating and issued a $56.00 target price on shares of Amedisys in a research note on Monday, June 5th. BidaskClub cut shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 12th. Mizuho cut shares of Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research report on Wednesday, July 26th. Bank of America Corporation assumed coverage on shares of Amedisys in a research report on Monday, August 21st. They set a “neutral” rating and a $55.00 price objective for the company. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $60.00 price objective on shares of Amedisys in a research report on Friday. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $56.44.
In related news, insider David B. Pearce sold 1,000 shares of the firm’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total value of $50,000.00. Following the completion of the transaction, the insider now owns 10,488 shares in the company, valued at approximately $524,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bruce D. Perkins acquired 2,000 shares of Amedisys stock in a transaction on Thursday, August 3rd. The shares were bought at an average price of $46.60 per share, with a total value of $93,200.00. Following the purchase, the director now directly owns 15,825 shares in the company, valued at approximately $737,445. The disclosure for this purchase can be found here. 2.80% of the stock is owned by company insiders.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with our FREE daily email newsletter.